EUROBIO-SCIENTIFIC (ALERS.PA) Stock Price, Forecast & Analysis
Europe - Euronext Paris - EPA:ALERS - FR0013240934 - Common Stock
ALERS.PA Key Statistics, Chart & Performance
The current stock price of ALERS.PA is 24.4 EUR. In the past month the price increased by 0.41%. In the past year, price decreased by -3.75%.
ALERS.PA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ARGX.BR | ARGENX SE | 65.57 | 42.91B | ||
| 1AE.DE | ARGENX SE | 63.14 | 41.33B | ||
| 22UA.DE | BIONTECH SE-ADR | N/A | 22.16B | ||
| 2X1.DE | ABIVAX SA | N/A | 8.11B | ||
| ABVX.PA | ABIVAX SA | N/A | 7.99B | ||
| GXE.DE | GALAPAGOS NV | N/A | 1.85B | ||
| GLPG.AS | GALAPAGOS NV | N/A | 1.88B | ||
| 5CV.DE | CUREVAC NV | 6.71 | 876.36M | ||
| IVA.PA | INVENTIVA SA | N/A | 929.30M | ||
| 6IV.DE | INVENTIVA SA | N/A | 834.75M | ||
| NANO.PA | NANOBIOTIX | N/A | 867.88M | ||
| PHIL.MI | PHILOGEN SPA | 19.56 | 652.05M |
Related stock screener links
About ALERS.PA
Company Profile
Eurobio-Scientific SA provides in vitro diagnostics solutions. The company is headquartered in Les Ulis, Ile-De-France and currently employs 380 full-time employees. The company went IPO on 2005-11-18. The company is engaged in activities ranging from discovery to the commercialization of specialty diagnostic products. The firm owns a portfolio of diagnostic products in three specialty areas: infectious diseases; Alzheimer's disease, and cancer. The company consists of Tetanos Quick Stick (TQS), which is an unitary test enabling to determine the tetanus vaccination status. The company has a portfolio of in-house and co-developed products, including AclarusDx (a blood-based test for the detection of biomarkers specific for Alzheimer's disease). The portfolio includes BJI Inoplex for prosthetic infections and EHT Dx14 for breast cancer (both in validation phase). The co-developed products include research programs for the identification of predictive biomarkers of response for anti-HER2 and anti-angiogenic therapies, among others. The company operates through Genbio and Eurobio Capforce Plus.
Company Info
EUROBIO-SCIENTIFIC
ZA de Courtaboeuf 7 Avenue de Scandinavie, Les Ulis Cedex
Les Ulis ILE-DE-FRANCE FR
Employees: 329
Phone: 331169796480
EUROBIO-SCIENTIFIC / ALERS.PA FAQ
What does EUROBIO-SCIENTIFIC do?
Eurobio-Scientific SA provides in vitro diagnostics solutions. The company is headquartered in Les Ulis, Ile-De-France and currently employs 380 full-time employees. The company went IPO on 2005-11-18. The company is engaged in activities ranging from discovery to the commercialization of specialty diagnostic products. The firm owns a portfolio of diagnostic products in three specialty areas: infectious diseases; Alzheimer's disease, and cancer. The company consists of Tetanos Quick Stick (TQS), which is an unitary test enabling to determine the tetanus vaccination status. The company has a portfolio of in-house and co-developed products, including AclarusDx (a blood-based test for the detection of biomarkers specific for Alzheimer's disease). The portfolio includes BJI Inoplex for prosthetic infections and EHT Dx14 for breast cancer (both in validation phase). The co-developed products include research programs for the identification of predictive biomarkers of response for anti-HER2 and anti-angiogenic therapies, among others. The company operates through Genbio and Eurobio Capforce Plus.
What is the current price of ALERS stock?
The current stock price of ALERS.PA is 24.4 EUR. The price increased by 1.46% in the last trading session.
Does EUROBIO-SCIENTIFIC pay dividends?
ALERS.PA does not pay a dividend.
What is the ChartMill rating of EUROBIO-SCIENTIFIC stock?
ALERS.PA has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
Should I buy ALERS stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on ALERS.PA.
What is EUROBIO-SCIENTIFIC worth?
EUROBIO-SCIENTIFIC (ALERS.PA) has a market capitalization of 250.10M EUR. This makes ALERS.PA a Micro Cap stock.
ALERS.PA Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to ALERS.PA. When comparing the yearly performance of all stocks, ALERS.PA is a bad performer in the overall market: 76.4% of all stocks are doing better.
ALERS.PA Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to ALERS.PA. ALERS.PA is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average.
ALERS.PA Financial Highlights
Over the last trailing twelve months ALERS.PA reported a non-GAAP Earnings per Share(EPS) of 0.23. The EPS decreased by -63.27% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 1.46% | ||
| ROA | 0.91% | ||
| ROE | 1.3% | ||
| Debt/Equity | 0.07 |
ALERS.PA Forecast & Estimates
For the next year, analysts expect an EPS growth of -11.36% and a revenue growth 22.03% for ALERS.PA